2000, Número 2
Referencias bibliográficas: 27
Archivo PDF: 36.02 Kb.
FRAGMENTOComo todos los años, los expertos en VIH/SIDA de todo el mundo esperan esta conferencia con la esperanza de que se repita el fenómeno observado en Vancouver 1996 durante la XI Conferencia Internacional de SIDA.
REFERENCIAS (EN ESTE ARTÍCULO)
Hope T, et al. Intracellular trafficking of HIV-1 particles and viral proteins. Abstract S26.
Sheeter D, et al. HIV-1 directly kills infected cells through disruption of mitochondria and activates caspase 9-induced apoptosis. Abstract 158.
Martínez-Picado J, et al. Selection of antiretroviral resistance in the latent reservoir of human immunodeficiency virus type 1 during successful therapy. Abstract 238.
Stellbrink HJ, et al. Influence of interleukin-2 (IL-2) on productive and latent HIV infection and on viral rebound. Abstract 240.
Korber B, et al. Timing the origin of the HIV-1 pandemic. Abstract L5.
Moore R, et al. Start HAART early (> 350 CD4+) or later? Evidence for greater effectiveness if started early. Abstract 522.
Tebas P, et al. When should we start? Use of Markov modeling and decision analysis to evaluate the long-term implications of antiretroviral therapy. Abstract 523.
Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Enero 19 del 2000.
Hammer S, et al. A randomized placebo-controlled trial of saquinavir, indinavir or nelfinavir in combination with amprenavir, abacavir, efavirenz & adefovir in patients with protease inhibitor failure. LB7.
García F. Structured cyclic antiretroviral therapy interruption in chronic infection may induce immune response against HIV-1 antigens associated with spontaneous drop in viral load. LB11.
Carcelain G, et al. Intermittent interruptions of antiretroviral therapy in chronically HIV-infected patients do not induce immune control of HIV. Abstract 356.
Orenstein JM, et al. Rapid activation of lymph nodes upon interrupting HAART in HIV-infected patients following prolonged viral suppression. Abstract 358.
Bartlett J, et al. Meta-analysis of efficacy of triple combination therapy in antiretroviral-naive HIV-1 infected adults. Abstract 519.
Tebas P, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. Abstract 207.
Hoy J, et al. Osteopenia in a randomized, multicenter study of protease inhibitor (PI) substitution in patients with thelipodystrophy syndrome and well-controlled HIV viremia. Abstract 208.
Klein D, et al. Do protease inhibitors increase the risk forcoronary heart disease among HIV-positive patients? Additional follow-up. Abstract 33.
Coplan P, et al. Myocardial infarction incidence in clinical trials of 4 protease inhibitors. Abstract 34.
Fiscus SA, et al. Increased use of maternal combination antiretroviral therapy and elective cesarean section to reduce perinatal HIV transmission in North Carolina. Abstract 706.
Peters V, et al. Trends to reduce perinatal HIV transmission in New York City. Abstract 707.
Quinn TC, et al. Viral load and risk of heterosexual transmission of HIV-1 among sexual partners. Abstract 193.
Blair J, et al. Do gender differences in viral load predict differences in HIV disease progression? Abstract 195.
Kuhn L, et al. HIV-1 specific T-helper cell responses detected at birth: Protection against intrapartum and breast feedingassociated transmission of HIV-1. Abstract 702.
Eron J, et al. The prospect for new agents in the management of treatment failure. Abstract S34.
Gulick R, et al. ABT-378/ritonavir in antiretroviral-naive HIV+ patients: 72 weeks. Abstract 515.
Deeks S, et al. ABT-378/ritonavir suppresses HIV RNA to < 400 copies/mL in 84% of PI-experienced patients at 48 weeks. Abstract 532.
Wang Y, et al. The safety, efficacy, and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in phase II study of antiretroviral-naive HIV-1 infected patients. Abstract 673.
Sanne I, et al. Safety and antiviral efficacy of a novel oncedaily HIV-1 protease inhibitor, BMS 232632: Preliminary results from a phase II clinical trial. Abstract 672.